1 Min Read
Dec 20 (Reuters) - UCB SA :
* Says Amgen and UCB announce submission of application for investigational osteoporosis medication romosozumab in Japan
Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.